Targeted Therapeutics for Cancer Treatment: A Review of Kinase Inhibitors, Angiogenesis Inhibitors, and Other Molecularly targeted Agents
Biotechnology Frontiers · 2025
DOI: 10.51470/bf.2025.5.1.09 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Frontiers, 2025. Verfasst von Moses Adondua Abah und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Targeted therapeutics have transformed modern oncology by offering precision, efficacy, and improved tolerability compared to conventional cytotoxic chemotherapy. This review synthesizes current advances in molecularly targeted cancer treatments, with a focus on kinase inhibitors, angiogenesis inhibitors, and other emerging classes of precision medicines. Kinase inhibitors remain central to targeted therapy, exploiting dysregulated signaling pathways such as Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), B-Rapidly Accelerated Fibrosarcoma (BRAF), Anaplastic Lymphoma Kinase (ALK), and Phosphatidylinositol 3-Kinase/AKT (PI3K/AKT) to halt tumor progression across diverse malignancies. Parallel progress in anti-angiogenic strategies has reshaped therapeutic approaches for solid tumors by disrupting Vascular Endothelial Growth Factor (VEGF)-mediated vascular growth and tumor nutrient supply. Beyond these established categories, newer targeted agents such as Poly (ADP-ribose) Polymerase (PARP) inhibitors, proteasome inhibitors, epigenetic modulators, and antibody drug conjugates are expanding the therapeutic landscape by exploiting tumor-specific vulnerabilities and introducing innovative mechanisms of action. Despite significant clinical benefits, challenges such as acquired resistance, tumor heterogeneity, limited biomarker accuracy, and therapy-related toxicity continue to constrain treatment outcomes. Addressing these barriers requires a deeper understanding of adaptive signaling networks, rational drug combinations, and integrative precision-medicine approaches. Emerging tools such as liquid biopsies, multi-omic profiling, and AI-driven decision systems hold promise for refining patient selection, predicting therapeutic responses, and guiding personalized interventions. This review provides a comprehensive and well-focused evaluation of established and evolving targeted therapies, highlighting their mechanisms, clinical applications, limitations, and future directions. By integrating current evidence and emerging innovations, it aims to offer a clear understanding of how molecularly targeted agents are reshaping the aspect of cancer treatment and to inspire continued research in this rapidly advancing field.
Zitieren
APA
Abah, M. A., Oladosu, M. A., Nnaemeka, N. J., & Agida, O. D. (2025). Targeted Therapeutics for Cancer Treatment: A Review of Kinase Inhibitors, Angiogenesis Inhibitors, and Other Molecularly targeted Agents. Biotechnology Frontiers. https://doi.org/10.51470/bf.2025.5.1.09
Vancouver
Abah MA, Oladosu MA, Nnaemeka NJ, Agida OD. Targeted Therapeutics for Cancer Treatment: A Review of Kinase Inhibitors, Angiogenesis Inhibitors, and Other Molecularly targeted Agents. Biotechnology Frontiers. 2025. doi:10.51470/bf.2025.5.1.09
BibTeX
@article{Abah2025,
author = {Abah, Moses Adondua and Oladosu, Micheal Abimbola and Nnaemeka, Nkwocha John and Agida, Ochuele Dominic},
title = {Targeted Therapeutics for Cancer Treatment: A Review of Kinase Inhibitors, Angiogenesis Inhibitors, and Other Molecularly targeted Agents},
journal = {Biotechnology Frontiers},
year = {2025},
doi = {10.51470/bf.2025.5.1.09}
}
EUVIMED